Beyond Tumour Size: Integrating Tumour Biology and Technical Quality to Select the Extent of Resection in Early-Stage NSCLC
European Journal of Cardio-Thoracic Surgery · 02.11.2026 · 68 (11-12)
DOI: 10.1093/ejcts/ezag228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 24.09.2026. Verfasst von Alessandro Brunelli. Beteiligte Einrichtung: Department of Thoracic Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom. Hauptthemen laut MEDLINE: Lung Neoplasms, Pneumonectomy, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 91 Literaturangaben.
Abstract (Originalsprache)
Importance Randomized trials have established anatomical segmentectomy as an acceptable alternative to lobectomy for selected patients with peripheral, node-negative Non Small Cell Lung Cancer (NSCLC) ≤2 cm. However, trial populations were highly selected, and tumour diameter alone does not capture the biological heterogeneity of early-stage disease.
Objective
To critically review the importance of tumour biology on outcomes following lobectomy or segmentectomy.
Design
A structured search of Undermind and PubMed identified comparative studies, randomized trials, meta-analyses, and consensus evidence available through August 10, 2026. Evidence was critically appraised and synthesized narratively, with emphasis on recurrence, survival, staging, and technical quality.
Results
Segmentectomy provides excellent outcomes when adequate margins, anatomical completeness, and rigorous nodal assessment are achieved. Ground-glass opacity (GGO)-dominant tumours, particularly those with low consolidation-to-tumour ratio (CTR), represent the strongest candidates for parenchymal preservation. Increasing CTR, pure-solid morphology, larger size, high Fluorodeoxyglucose (FDG) uptake, micropapillary or solid histology, spread through air spaces (STAS), visceral pleural invasion, and lymphovascular invasion identify progressively higher-risk phenotypes, but none alone consistently proves that lobectomy improves survival. Micropapillary components exceeding approximately 5%, STAS, inadequate margins, incomplete staging, and multiple coexisting adverse features strengthen the rationale for lobectomy. Segmentectomy is generally preferable to wedge resection for solid, deeper, or biologically aggressive lesions, whereas wedge resection remains reasonable for carefully selected small, peripheral, GGO-dominant tumours. The favourable results of randomized trials depend on accurate preoperative and intraoperative staging and should not be generalized to unselected cT1c or biologically aggressive tumours. Conclusions and Relevance Sublobar resection should be viewed as refined selection rather than replacement of lobectomy. Tumour size defines eligibility, but biology increasingly determines suitability. Precision surgery will require prospective validation of integrated models combining morphology, metabolism, pathology, molecular biomarkers, patient physiology, and technical quality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom.
- School of Medicine, University of Leeds, Leeds, United Kingdom.
ORCID-Profile: Alessandro Brunelli
Zitieren
APA
Brunelli, A. (2026). Beyond Tumour Size: Integrating Tumour Biology and Technical Quality to Select the Extent of Resection in Early-Stage NSCLC. European Journal of Cardio-Thoracic Surgery, 68(11-12). https://doi.org/10.1093/ejcts/ezag228
Vancouver
Brunelli A. Beyond Tumour Size: Integrating Tumour Biology and Technical Quality to Select the Extent of Resection in Early-Stage NSCLC. European Journal of Cardio-Thoracic Surgery. 2026;68(11-12). doi:10.1093/ejcts/ezag228
BibTeX
@article{Brunelli2026,
author = {Brunelli, Alessandro},
title = {Beyond Tumour Size: Integrating Tumour Biology and Technical Quality to Select the Extent of Resection in Early-Stage NSCLC},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2026},
volume = {68},
number = {11-12},
doi = {10.1093/ejcts/ezag228}
}
EUVIMED